Videos | Structural Heart | April 03, 2020

VIDEO: TAVR Performs Well in Bicuspid Aortic Valve Patients

Basel Ramlawi, M.D., chairman of The Heart and Vascular Center at Valley Health System in Virginia, director of the Advanced Valve and Aortic Center, and co-principal investigator for an American College of Cardiology (ACC) 2020 Scientific Session late-breaking trial that looks at the clinical implications of TAVR in patients who have bicuspid aortic valve leaflets offers an overview of the data from ACC.20.

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the ACC 2020. The session was part of the virtual, online late-breaking presentations, since the live meeting was cancelled due to the spread of COVID-19. 

TAVR has become increasingly popular in recent years as a less-invasive alternative to open-heart valve replacement surgery. However, few studies have examined its safety in patients with a bicuspid valve, a genetic variation of the aortic valve in some patients, rather than the typic three-leaflet valve. The condition affecting roughly 2-5 percent of people in which two of the three flaps in the aortic valve are fused together.

A bicuspid valve is more likely to become stenosis. Valve replacement, either through TAVR or open-heart surgery, is the main treatment option available for people with severe aortic stenosis, which causes fatigue and other symptoms and raises the risk of other heart problems when left untreated. The new study is the first to prospectively examine TAVR’s safety for treating severe aortic stenosis in relatively young, healthy patients—in whom open-heart surgery would pose a low risk—who have a bicuspid valve. It also is one of the first studies involving such patients in which doctors used a newer self-expanding artificial valve.

“This clearly has clinical implications with patients with bicuspid valves who want TAVR," said Basel Ramlawi, M.D., cardiothoracic surgeon at Valley Health System in Virginia and the study’s co-principal investigator. "TAVR with a self-expanding prosthesis is a very viable and safe procedure in low-risk bicuspid patients and achieved excellent early results. Though additional follow-up is necessary to determine long-term outcomes, early results suggest this procedure can be performed successfully in low-risk individuals with a good outcome.” 

The study prospectively tracked 150 patients who underwent TAVR at 25 medical centers in the U.S. 

Read the aricle on the study


Find more ACC news and video




Recent Videos View all 644 items

Sponsored Videos View all 46 items

Cardiovascular Ultrasound | July 20, 2022

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it easy for users to interpret what they are seeing. The TrueVue feature enhances the sense of depth and space, producing images that appear natural and realistic to the human eye.  

Watch the video to check out how TrueVue can help improve views of LAA and MV morphology. 

Cardiovascular Ultrasound | July 07, 2022

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to every echo exam. The AI-empowered algorithm delivers fast and consistent measurements – in half the time of manual methods.*  

Watch the video to see how you can put “smart”  to work with the latest AI-powered quantification tools. 

*External study with external sonographers comparing the results of 18 exams with and without AutoMeasure

Cardiovascular Ultrasound | June 14, 2022

The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased array transducer. When combined with nSIGHT Plus image formation on the EPIQ CVx cardiology ultrasound system, the X5-1c transducer enables image quality rarely seen from a transthoracic transducer. 

Watch the video to learn about the benefits which may include decreased exam time due to faster access to echo windows, increased confidence in quantification results and more. 

Cardiovascular Ultrasound | May 31, 2022

Philips recently announced an update to their flagship EPIQ CVx premium cardiology ultrasound system. Watch the video to learn about the latest features including the next-generation nSIGHT Plus imaging architecture system that leverages both hardware and software to support sophisticated image formation and enhanced image quality.

Conference Coverage View all 460 items

Cath Lab View all 316 items

Cardiac Imaging View all 287 items

Cardiac Diagnostics View all 78 items

EP Lab View all 83 items

Information Technology View all 169 items

Subscribe Now